We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.6B
AUM Growth
+$272M
Cap. Flow
+$580M
Cap. Flow %
22.28%
Top 10 Hldgs %
59.11%
Holding
341
New
89
Increased
83
Reduced
62
Closed
85

Sector Composition

Rank Sector Weight
1 Miscellaneous 92.32%
2 Healthcare 6.56%
3 Energy 0.47%
4 Consumer Discretionary 0.36%
5 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LRMR icon
51
Larimar Therapeutics
LRMR
$393M
$6.44M 0.25%
+27,297
New +$6.19M
HZNP
52
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.09M 0.23%
+4,963
New +$57.7K
MBOT icon
53
Microbot Medical
MBOT
$97.4M
$6.08M 0.23%
+2,979
New +$7.86M
ALNY icon
54
PUT
Alnylam Pharmaceuticals
ALNY
$33.5B
$6.04M 0.23%
773
-303
-28% -$19.5K
COV
55
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$5.78M 0.22%
+66,752
New +$5.91M
ALKS icon
56
CALL
Alkermes
ALKS
$7.69B
$5.74M 0.22%
1,339
-62
-4% -$2.78K
APEN
57
DELISTED
Apollo Endosurgery, Inc.
APEN
$5.73M 0.22%
+21,144
New +$5.74M
ARCT icon
58
PUT
Arcturus Therapeutics
ARCT
$435M
$5.65M 0.22%
523
+495
+1,768% +$64.5K
TEVA icon
59
CALL
Teva Pharmaceuticals
TEVA
$45.1B
$5.61M 0.22%
1,044
-5,826
-85% -$309K
PBYI icon
60
PUT
Puma Biotechnology
PBYI
$471M
$5.58M 0.21%
234
+190
+432% +$39K
AKTX
61
Akari Therapeutics
AKTX
$22M
$5.06M 0.19%
108
+6
+6% +$280K
RMTI icon
62
PUT
Rockwell Medical
RMTI
$32.1M
$4.76M 0.18%
47
-2
-4% -$2.26K
SHPG
63
DELISTED
Shire pic
SHPG
$4.74M 0.18%
+9,955
New +$2.47M
SGMO
64
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.53M 0.17%
420,123
-23,163
-5% -$303K
OCUL icon
65
Ocular Therapeutix
OCUL
$2.35B
$4.45M 0.17%
+297,107
New +$4.39M
THMO
66
DELISTED
ThermoGenesis Holdings, Inc. Common Stock
THMO
$4.33M 0.17%
395
+26
+7% +$313K
TSRO
67
CALL
DELISTED
TESARO, Inc.
TSRO
$4.33M 0.17%
1,607
+326
+25% +$9.58K
QRHC icon
68
Quest Resource Holding
QRHC
$28.9M
$4M 0.15%
+290,473
New +$8.96M
ACHN
69
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
$3.93M 0.15%
3,938
+2,261
+135% +$21K
BLUE
70
CALL
DELISTED
bluebird bio
BLUE
$3.56M 0.14%
77
+24
+45% +$11.1K
MNKD icon
71
MannKind Corp
MNKD
$1.21B
$3.46M 0.13%
+116,984
New +$4.62M
RPRX
72
PUT
DELISTED
Repros Therapeutics Inc.
RPRX
$3.42M 0.13%
3,460
+10
+0.3% +$148
BCLI
73
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$3.32M 0.13%
+53,884
New +$3.32M
DRNA
74
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.31M 0.13%
260,000
+107,006
+70% +$1.61M
SLXP
75
CALL
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$3.13M 0.12%
200
+63
+46% +$9.13K

Similar funds

Sabby Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sabby Management held 341 positions worth $2.6B, up 12% from $2.33B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management deployed $580M of net new capital in Q3 2014, opening 89 new positions and adding to 83 existing holdings. Its largest new stake was Acadia Healthcare: 663,324 shares worth $16.4M.

By sector, the portfolio is most concentrated in Miscellaneous at 92% of assets, up from 87% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was SALIX PHARMACEUTICALS LTD DEL, an estimated $6.87M trimmed.

  • Sabby Management's largest Q3 2014 buy was Acadia Healthcare: 663,324 shares worth $16.4M.
  • Sabby Management added most to AstraZeneca in Q3 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $6.87M.
  • Sabby Management fully exited Weyerhaeuser in Q3 2014, selling an estimated $64.6M.
  • Sabby Management's ten largest holdings make up 59% of its $2.6B portfolio in Q3 2014.
  • Sabby Management opened 89 new positions and closed 85 in Q3 2014.
  • Sabby Management's portfolio value rose 12% quarter-over-quarter to $2.6B.

Based on Sabby Management's 13F filing for Q3 2014, filed 14 Nov 2014.